Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
Why the study?
Do beta-blockers reduce all-cause and cardiovascular mortality in patients with heart failure across different LVEF strata?
Population
17,312 patients with heart failure from 11 trials, including 14,262 in sinus rhythm and 3,050 in atrial…
Comparison
Beta-blockers vs Placebo
Design
Meta-analysis, randomized, double-blind
Follow-up
1.3 years median
Authors
Discussion
Loading...
Member takes
Implication
Supports routine beta-blocker use for mildly reduced ejection fraction in sinus rhythm.
Structured PICO
Do beta-blockers reduce all-cause and cardiovascular mortality in patients with heart failure across different LVEF strata?
P
Population
17,312 patients with heart failure from 11 trials, including 14,262 in sinus rhythm (median LVEF 27%, 575 with LVEF 40-49%, 244 ≥ 50%) and 3,050 in atrial fibrillation.
I
Intervention
Beta-blockers
C
Comparator
Placebo
O
Outcome
All-cause mortality and cardiovascular death over 1.3 years median follow-uphard clinical
Beta-blockers improve prognosis for heart failure patients in sinus rhythm with LVEF <40% and similarly in those with LVEF 40-49%, but do not improve prognosis in those with atrial fibrillation.
Cite This Study
Cleland et al. (2017) studied this question.